Different contribution of chemokine N-terminal features attest a different ligand binding mode and a bias towards activation of the atypical chemokine receptor ACKR3/CXCR7 compared to CXCR4 and CXCR3
Szpakowska, Martyna; Nevins, Amanda M; Meyrath, Max Marc Rogeret al.
2018 • In British Journal of Pharmacology, 175 (9), p. 1419-1438
[en] Background and purpose
Chemokines and their receptors form an intricate interaction and signaling network that plays critical roles in various physiological and pathological cellular processes. The high promiscuity and apparent redundancy of this network makes probing individual chemokine/receptor interactions and functional effects, as well as targeting individual receptor axes for therapeutic applications, challenging. Despite poor sequence identity, the N-terminal regions of chemokines, which play a key role in their activity and selectivity, harbor several conserved features. Thus far, little is known regarding the molecular basis of their interactions with conventional vs. atypical chemokine receptors or the conservation of their contributions across chemokine-receptor pairs.
Experimental Approach
In this study, using a broad panel of chemokine variants and modified peptides derived from the N-terminal region of chemokines CXCL12, CXCL11, and vCCL2, we compare the role of various features in binding and activation of their shared receptors, the two canonical G protein-signaling receptors, CXCR4 and CXCR3, as well as the atypical scavenger receptor CXCR7/ACKR3, which shows exclusively arrestin-dependent activity.
Key Results
We provide exhaustive molecular insights into the plasticity of the ligand-binding pockets of these receptors, their chemokine binding modes, and their activation mechanisms. We show that, although the chemokine N-terminal region is a critical determinant, neither the most proximal residues nor the N-loop are essential for ACKR3 binding and activation, as opposed to CXCR4 and CXCR3.
Conclusion and Implications
These results suggest a different interaction mechanism between this atypical receptor and its ligands and illustrates its strong propensity to activation.
Different contribution of chemokine N-terminal features attest a different ligand binding mode and a bias towards activation of the atypical chemokine receptor ACKR3/CXCR7 compared to CXCR4 and CXCR3
Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA et al. (2017a). The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. Br J Pharmacol 174: S17–S129.
Alexander SPH, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E et al. (2017b). The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. Br J Pharmacol 174: S272–S359.
Allen SJ, Crown SE, Handel TM (2007). Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25: 787–820.
Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ et al. (2014a). International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev 66: 1–79.
Bachelerie F, Graham GJ, Locati M, Mantovani A, Murphy PM, Nibbs R et al. (2014b). New nomenclature for atypical chemokine receptors. Nat Immunol 15: 207–208.
Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B et al. (2005). The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 280: 35760–35766.
Balkwill F (2004). Cancer and the chemokine network. Nat Rev Cancer 4: 540–550.
Ballesteros JA, Weinstein H (1995). Integrated methods for the construction of three-dimensional models and computational probing of structure–function relations in G protein-coupled receptors. In: Sealfon SC Conn PM, (eds.) Methods in Neurosciences, Vol. 25. Academic Press: San Diego, CA. pp. 366–428.
Benredjem B, Girard M, Rhainds D, St-Onge G, Heveker N (2017). Mutational analysis of atypical chemokine receptor 3 (ACKR3/CXCR7) interaction with its chemokine ligands CXCL11 and CXCL12. J Biol Chem 292: 31–42.
Berahovich RD, Zabel BA, Lewen S, Walters MJ, Ebsworth K, Wang Y et al. (2014). Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels. Immunology 141: 111–122.
Berchiche YA, Gravel S, Pelletier ME, St-Onge G, Heveker N (2011). Different effects of the different natural CC chemokine receptor 2b ligands on beta-arrestin recruitment, Galphai signaling, and receptor internalization. Mol Pharmacol 79: 488–498.
Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A et al. (1997). Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 71: 7478–7487.
Boldajipour B, Mahabaleshwar H, Kardash E, Reichman-Fried M, Blaser H, Minina S et al. (2008). Control of chemokine-guided cell migration by ligand sequestration. Cell 132: 463–473.
Burg JS, Ingram JR, Venkatakrishnan AJ, Jude KM, Dukkipati A, Feinberg EN et al. (2015). Structural biology. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor. Science 347: 1113–1117.
Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z et al. (2006). A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203: 2201–2213.
Chevigne A, Fievez V, Schmit JC, Deroo S (2011). Engineering and screening the N-terminus of chemokines for drug discovery. Biochem Pharmacol 82: 1438–1456.
Chevigne A, Fievez V, Szpakowska M, Fischer A, Counson M, Plesseria JM et al. (2014). Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection. Biochim Biophys Acta 1843: 1031–1041.
Choi WT, Kumar S, Madani N, Han X, Tian S, Dong CZ et al. (2012). A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry. Biochemistry 51: 7078–7086.
Clark-Lewis I, Mattioli I, Gong JH, Loetscher P (2003). Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 278: 289–295.
Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP et al. (1998). Interferon-inducible T cell alpha chemoattractant 0(I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187: 2009–2021.
Crump MP, Elisseeva E, Gong J, Clark-Lewis I, Sykes BD (2001). Structure/function of human herpesvirus-8 MIP-II (1-71) and the antagonist N-terminal segment (1-10). FEBS Lett 489: 171–175.
Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F et al. (1997). Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 16: 6996–7007.
Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
Dixon AS, Schwinn MK, Hall MP, Zimmerman K, Otto P, Lubben TH et al. (2016). NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells. ACS Chem Biol 11: 400–408.
Dyer DP, Salanga CL, Volkman BF, Kawamura T, Handel TM (2016). The dependence of chemokine-glycosaminoglycan interactions on chemokine oligomerization. Glycobiology 26: 312–326.
Fernandez EJ, Lolis E (2002). Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 42: 469–499.
Ganju RK, Brubaker SA, Meyer J, Dutt P, Yang Y, Qin S et al. (1998). The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem 273: 23169–23175.
Gustavsson M, Wang L, van Gils N, Stephens BS, Zhang P, Schall TJ et al. (2017). Structural basis of ligand interaction with atypical chemokine receptor 3. Nat Commun 8: 14135.
Hanes MS, Salanga CL, Chowdry AB, Comerford I, McColl SR, Kufareva I et al. (2015). Dual targeting of the chemokine receptors CXCR4 and ACKR3 with novel engineered chemokines. J Biol Chem 290: 22385–22397.
Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S et al. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucl Acids Res 46: D1091-D1106.
Heise CE, Pahuja A, Hudson SC, Mistry MS, Putnam AL, Gross MM et al. (2005). Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther 313: 1263–1271.
Heveker N, Montes M, Germeroth L, Amara A, Trautmann A, Alizon M et al. (1998). Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides. Curr Biol 8: 369–376.
Heveker N, Tissot M, Thuret A, Schneider-Mergener J, Alizon M, Roch M et al. (2001). Pharmacological properties of peptides derived from stromal cell-derived factor 1: study on human polymorphonuclear cells. Mol Pharmacol 59: 1418–1425.
Ikeda Y, Kumagai H, Skach A, Sato M, Yanagisawa M (2013). Modulation of circadian glucocorticoid oscillation via adrenal opioid-CXCR7 signaling alters emotional behavior. Cell 155: 1323–1336.
Janssens R, Mortier A, Boff D, Ruytinx P, Gouwy M, Vantilt B et al. (2017). Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes. Biochem Pharmacol 132: 92–101.
Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N (2009). AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 75: 1240–1247.
Kaya AI, Onaran HO, Ozcan G, Ambrosio C, Costa T, Balli S et al. (2012). Cell contact-dependent functional selectivity of beta2-adrenergic receptor ligands in stimulating cAMP accumulation and extracellular signal-regulated kinase phosphorylation. J Biol Chem 287: 6362–6374.
Kledal TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S et al. (1997). A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 277: 1656–1659.
Kleist AB, Getschman AE, Ziarek JJ, Nevins AM, Gauthier PA, Chevigne A et al. (2016). New paradigms in chemokine receptor signal transduction: moving beyond the two-site model. Biochem Pharmacol 114: 53–68.
Kufareva I, Stephens BS, Holden LG, Qin L, Zhao C, Kawamura T et al. (2014). Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: molecular modeling and experimental validation. Proc Natl Acad Sci U S A 111: E5363–E5372.
Leduc M, Breton B, Gales C, Le Gouill C, Bouvier M, Chemtob S et al. (2009). Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. J Pharmacol Exp Ther 331: 297–307.
Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B (2009). CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 113: 6085–6093.
Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I et al. (1996). Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184: 963–969.
Loetscher P, Gong JH, Dewald B, Baggiolini M, Clark-Lewis I (1998). N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities. J Biol Chem 273: 22279–22283.
Ludwig A, Schiemann F, Mentlein R, Lindner B, Brandt E (2002). Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. J Leukoc Biol 72: 183–191.
Luker KE, Steele JM, Mihalko LA, Ray P, Luker GD (2010). Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene 29: 4599–4610.
Luo Z, Fan X, Zhou N, Hiraoka M, Luo J, Kaji H et al. (2000). Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II. Biochemistry 39: 13545–13550.
Montpas N, Cabana J, St-Onge G, Gravel S, Morin G, Kuroyanagi T et al. (2015). Mode of binding of the cyclic agonist peptide TC14012 to CXCR7: identification of receptor and compound determinants. Biochemistry 54: 1505–1515.
Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG et al. (2010). CXCR7 functions as a scavenger for CXCL12 and CXCL11. PloS one 5: e9175.
Oishi S, Kuroyanagi T, Kubo T, Montpas N, Yoshikawa Y, Misu R et al. (2015). Development of novel CXC chemokine receptor 7 (CXCR7) ligands: selectivity switch from CXCR4 antagonists with a cyclic pentapeptide scaffold. J Med Chem 58: 5218–5225.
Oswald C, Rappas M, Kean J, Dore AS, Errey JC, Bennett K et al. (2016). Intracellular allosteric antagonism of the CCR9 receptor. Nature 540: 462–465.
Princen K, Hatse S, Vermeire K, De Clercq E, Schols D (2003). Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry. Cytometry A 51: 35–45.
Proost P, Mortier A, Loos T, Vandercappellen J, Gouwy M, Ronsse I et al. (2007). Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 110: 37–44.
Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G et al. (2001). Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 98: 3554–3561.
Proost P, Struyf S, Schols D, Durinx C, Wuyts A, Lenaerts JP et al. (1998). Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett 432: 73–76.
Qin L, Kufareva I, Holden LG, Wang C, Zheng Y, Zhao C et al. (2015). Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science 347: 1117–1122.
Rajagopal S, Bassoni DL, Campbell JJ, Gerard NP, Gerard C, Wehrman TS (2013). Biased agonism as a mechanism for differential signaling by chemokine receptors. J Biol Chem 288: 35039–35048.
Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP et al. (2010). Beta-arrestin- but not G protein-mediated signaling by the ‘decoy’ receptor CXCR7. Proc Natl Acad Sci U S A 107: 628–632.
Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S (2004). CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 25: 201–209.
Rossi D, Zlotnik A (2000). The biology of chemokines and their receptors. Annu Rev Immunol 18: 217–242.
Steen A, Larsen O, Thiele S, Rosenkilde MM (2014). Biased and g protein-independent signaling of chemokine receptors. Front Immunol 5: 277.
Sun Y, Cheng Z, Ma L, Pei G (2002). Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem 277: 49212–49219.
Szpakowska M, Chevigne A (2015). vCCL2/vMIP-II, the viral master KEYmokine. J Leukoc Biol 99: 893–900.
Szpakowska M, Dupuis N, Baragli A, Counson M, Hanson J, Piette J et al. (2016). Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7. Biochem Pharmacol 114: 14–21.
Szpakowska M, Fievez V, Arumugan K, van Nuland N, Schmit JC, Chevigne A (2012). Function, diversity and therapeutic potential of the N-terminal domain of human chemokine receptors. Biochem Pharmacol 84: 1366–1380.
Takekoshi T, Ziarek JJ, Volkman BF, Hwang ST (2012). A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4-expressing melanoma cells due to enhanced serum stability. Mol Cancer Ther 11: 2516–2525.
Veldkamp CT, Seibert C, Peterson FC, De la Cruz NB, Haugner JC 3rd, Basnet H et al. (2008). Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci Signal 1: ra4.
Watts AO, van Lipzig MM, Jaeger WC, Seeber RM, van Zwam M, Vinet J et al. (2013). Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexes. Br J Pharmacol 168: 1662–1674.
Wijtmans M, Maussang D, Sirci F, Scholten DJ, Canals M, Mujic-Delic A et al. (2012). Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists. Eur J Med Chem 51: 184–192.
Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V et al. (2010). Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330: 1066–1071.
Zheng Y, Han GW, Abagyan R, Wu B, Stevens RC, Cherezov V et al. (2017). Structure of CC chemokine receptor 5 with a potent chemokine antagonist reveals mechanisms of chemokine recognition and molecular mimicry by HIV. Immunity 46: 1005, `e1005–1017.
Zheng Y, Qin L, Zacarias NV, de Vries H, Han GW, Gustavsson M et al. (2016). Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature 540: 458–461.
Zhou N, Luo Z, Luo J, Fan X, Cayabyab M, Hiraoka M et al. (2002). Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines. J Biol Chem 277: 17476–17485.
Zhou N, Luo Z, Luo J, Hall JW, Huang Z (2000). A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II. Biochemistry 39: 3782–3787.
Zlotnik A, Yoshie O (2012). The chemokine superfamily revisited. Immunity 36: 705–716.
Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR (1998). Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393: 595–599.